miR-195 was shown to inhibit cyclin D1 in HCC and breast cancer (Xu et al., 2009;Li et al., 2011a), CCND3 in glioblastoma (Zhang et al., 2012), CDK4 in bladder cancer (Lin et al., 2012), CDK6 in HCC (Xu et al., 2009), E2F3 in HCC and glioblastoma (Xu et al., 2009;Zhang et al., 2012), BCL-2 in breast and colorectal cancer (Liu et al., 2010;Singh and Saini, 2012), RAF1 in breast cancer (Li et al., 2011a), and GLUT3 in bladder cancer (Fei et al., 2012). Here, CCND1 is linked to breast carcinoma.